

Lack of benefits of mammalian target of rapamycin ...

<https://aasidpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.24429>

See Article on Page 627. Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) generally carries a dismal prognosis, with fewer than 10% amenable to resection and a median survival of only a year from diagnosis. 1, 2 Despite adherence to the Milan criteria, 3 HCC still recurs in 10%-15% after LT. 1 It has been postulated that calcineurin inhibitors (CNIs) may amplify HCC recurrence risk. 4 Immunosuppression based on mammalian target of rapamycin ...

Cited by: 4 Author: Neil Mehta, John P. Roberts, Francis Y. Yao
Publish Year: 2016

Survival Benefit of Liver Transplantation for ...

<https://journals.lww.com/transplantjournal/...>

Introduction Materials and Methods Results Discussion

The rising prevalence of hepatitis C virus (HCV) and nonalcoholic fatty liver disease has led to a marked increase in the incidence of cirrhosis and hepatocellular carcinoma (HCC).¹ For patients with early-stage HCC, there are 3 curative options—ablation, hepatic resection, and liver transplant (LT).²⁻⁴ Since the inception of model for end-stage liver disease (MELD)-based allocation in 2002, waitlisted patients with HCC within Milan criteria have been eligible for automatic MELD exception point...

See more on journals.lww.com

PEOPLE ALSO ASK

- Which is the best liver transplant for HCC? ▾
- What is the survival benefit of Lt over ablation? ▾
- What is the trend in transplantation? ▾

Feedback

Liver Transplantation for Hepatocellular Carcinoma: A ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736995>

Mammalian Target of Rapamycin Inhibitors Are Associated ...

<https://pubmed.ncbi.nlm.nih.gov/24943720>
Abstract. Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased risk of post-transplant hepatocellular carcinoma (HCC) recurrence. The mammalian target of rapamycin inhibitors (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.

Cited by: 158 Author: Evangelos Cholongitis, Chrysantli Mari...
Publish Year: 2014

Lack of benefits of mammalian target of rapamycin ...

<https://aastipubs.onlineibrary.wiley.com/doi/full/10.1002/lt.24429>
Mar 05, 2019 - See Article on Page 927. Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) generally carries a dismal prognosis, with fewer than 10% amenable to resection and a median survival of only a year from diagnosis. 1, 2 Despite adherence to the Milan criteria, 3 HCC still recurs in 10%-15% after LT. 1 It has been postulated that calcineurin inhibitors (CNIs) may amplify HCC recurrence risk. 4 Immunosuppression based on mammalian target of rapamycin ...

Cited by: 4 Author: Neil Mehta, John P. Roberts, Francis Y. Yao
Publish Year: 2018

Survival Benefit of Liver Transplantation for ...


<https://journals.lww.com/transplantjournal/>
INTRODUCTION: The rising prevalence of hepatitis C virus (HCV) and nonalcoholic fatty liver disease has led to a marked increase in the incidence of cirrhosis and hepatocellular carcinoma (HCC). 1 For

Chatting with a search engine is so cool, right?

Say something...

Hepatocellular Carcinoma

Medical Condition



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

📊 Rare (Fewer than 200,000 cases per year in US)

👉 May be preventable by vaccine

🏥 Often requires lab test or imaging

🏥 Treatable by a medical professional



Name of Journal: *World Journal of Gastrointestinal Surgery*
Manuscript NO: 64372
Manuscript Type: MINIREVIEWS

Trends of Rapamycin in Survival Benefits of Liver Transplantation for Hepatocellular Carcinoma

Rapamycin in hepatocellular carcinoma after transplantation

Yang Zhao, Yu Liu, Lin Zhou, Guo-sheng Du, Qiang He

Match Overview

Match #	Source	Words	Match %
1	Internet	49 words	1%
	crawled on 30-Aug-2019 tessera.spandidos-publications.com		
2	Internet	20 words	<1%
	crawled on 08-Jul-2019 www.mpacjournals.com		
3	Crossref	19 words	<1%
	Sam E. Glegg, Gino I. Sam, Paul J. Gow, Neville D. Yeomans. "Systematic review with meta-analysis: sorafenib or everolimus for advanced hepatocellular carcinoma." <i>Cochrane Database of Systematic Reviews</i> 2014, Issue 12. doi:10.1002/14651925.cd010547		
4	Crossref	19 words	<1%
	Yu Sun, Shuai Zhao, Xiaoli Li, Liang Yan, Jingcheng Wang, Dixin Wang, Hui Chen, Jihang Dai, Jun He. "Local application of rapamycin in the treatment of hepatocellular carcinoma." <i>World Journal of Gastroenterology</i> 2014, 20(46):14053-14058. doi:10.3745/j.wjg.v20.i46.14053		
5	Internet	18 words	<1%
	crawled on 17-May-2020 insights.ovid.com		
6	Crossref	17 words	<1%
	Andrea Y. Cho, Daniel K. Choo, J. Joseph Kim, David B. Weiner. "Chapter 8 DNA Vaccination in Immunotherapy of Hepatocellular Carcinoma." <i>Immunotherapy of Hepatocellular Carcinoma</i> 2014, pp. 115-130. doi:10.1007/978-1-4939-9888-8_8		
7	Internet	17 words	<1%
	www.ncbi.nlm.nih.gov		
8	Internet	13 words	<1%
	crawled on 18-Oct-2020		

国内版

国际版

Trends of rapamycin in survival benefits of liver transplantation for



ALL

IMAGES

VIDEOS

12,800 Results

Any time ▾

Lack of benefits of mammalian target of rapamycin ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.24429>

Mar 08, 2016 · See Article on Page 627. Recurrent **hepatocellular carcinoma** (HCC) after **liver transplantation** (LT) generally carries a dismal prognosis, with fewer than 10% amenable to resection and a median **survival** of only a year from diagnosis. 1, 2 Despite adherence to the Milan criteria, 3 HCC still recurs in 10%-15% after LT. 1 It has been postulated that calcineurin inhibitors (CNIs) may amplify HCC recurrence risk. 4 Immunosuppression based on mammalian target of **rapamycin** ...

Cited by: 4

Author: Neil Mehta, John P. Roberts, Francis Y. Yao

Publish Year: 2016

Survival Benefit of Liver Transplantation for ...

<https://journals.lww.com/transplantjournal/...>

INTRODUCTION. The rising prevalence of hepatitis C virus (HCV) and nonalcoholic fatty liver disease has led to a marked increase in the incidence of cirrhosis and **hepatocellular carcinoma** (HCC). 1 For patients with early-stage HCC, there are 3 curative options—ablation, hepatic resection, and **liver transplant** (LT). 2-4 Since the inception of model for end-stage liver disease (MELD)-based ...

Multidisciplinary approach for post-liver transplant ...

<https://pubmed.ncbi.nlm.nih.gov/30568386>

A large number of **liver transplants** have been performed for **hepatocellular carcinoma** (HCC), and recurrence is increasingly encountered. The recurrence of HCC after **liver transplantation** is notoriously difficult to manage. We hereby propose multi-disciplinary management with a systematic approach. Th ...

Cited by: 24

Author: Kin Pan Au, Kenneth Siu Ho Chok

Publish Year: 2018

Sirolimus-based immunosuppression in liver transplantation ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.22441>

Sep 30, 2011 · The meta-analysis showed that in comparison with an SRL-free regimen, an SRL-based regimen improved 1-year **patient survival** (OR = 4.53, 95% CI = 2.31-8.89, $P < 0.001$). There was no significant heterogeneity between the studies ($\chi^2 = 0.05$, $P = 0.97$). Two studies reported 3-year **patient survival** (2718 participants).

Cited by: 174

Author: Wenhua Liang, Dongping Wang, Xiaoting ...

Publish Year: 2012